or Try an Advanced Search...

    Technical Analysis for ZVSA - ZyVersa Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 1.91 -4.98% -0.10
    ZVSA closed down 4.98 percent on Friday, November 1, 2024, on 38 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical ZVSA trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    180 Bearish Setup Bearish Swing Setup 0.00%
    Reversal New Lows Setup Bearish Swing Setup 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    New 52 Week Low Weakness 0.00%
    Stochastic Reached Oversold Weakness 0.00%
    Outside Day Range Expansion 0.00%
    Below Lower BB Weakness 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Older End-of-Day Signals for ZVSA ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 21 hours ago
    New 52 Week Low about 21 hours ago
    Rose Above Previous Day's High 1 day ago
    Outside Day 1 day ago
    Down 3% 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ZVSA Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates that address high unmet medical needs in the areas of renal and inflammatory diseases. ZyVersa's development pipeline includes phase 2a ready VAR 200, a cholesterol efflux mediator for treatment of rare kidney disease, focal segmental glomerulosclerosis. ZyVersa believes VAR 200 has potential to treat other glomerular diseases, including Alport syndrome and diabetic kidney disease. ZyVersa's development pipeline also includes IC 100, a novel inflammasome ASC inhibitor being developed to treat a multitude of inflammatory diseases.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Organ Systems Inflammatory Diseases Kidney Disease Kidney Diabetic Nephropathy Alport Syndrome Diabetic Kidney Disease Focal Segmental Glomerulosclerosis Glomerulosclerosis Inflammasome Stage Specialty Biopharmaceutical

    Is ZVSA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 22 ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
    Oct 17 ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months
    Oct 15 ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors
    Oct 7 ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications
    Sep 17 Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
    Sep 3 ZyVersa Therapeutics files for mixed shelf offering
    Aug 7 ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation
    Jul 29 ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults
    Jul 25 ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
    Jul 18 ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
    See more ZVSA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 42.385
    52 Week Low 1.88
    Average Volume 148,587
    200-Day Moving Average 4.79
    50-Day Moving Average 2.37
    20-Day Moving Average 2.20
    10-Day Moving Average 2.09
    Average True Range 0.15
    RSI (14) 26.47
    ADX 31.01
    +DI 7.95
    -DI 26.25
    Chandelier Exit (Long, 3 ATRs) 1.94
    Chandelier Exit (Short, 3 ATRs) 2.33
    Upper Bollinger Bands 2.46
    Lower Bollinger Band 1.93
    Percent B (%b) -0.04
    BandWidth 24.20
    MACD Line -0.12
    MACD Signal Line -0.11
    MACD Histogram -0.015
    Fundamentals Value
    Market Cap 3.14 Million
    Num Shares 1.64 Million
    EPS -78.43
    Price-to-Earnings (P/E) Ratio -0.02
    Price-to-Sales 0.00
    Price-to-Book 0.05
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.20
    Resistance 3 (R3) 2.22 2.15 2.15
    Resistance 2 (R2) 2.15 2.07 2.14 2.13
    Resistance 1 (R1) 2.03 2.03 1.99 2.01 2.12
    Pivot Point 1.95 1.95 1.94 1.94 1.95
    Support 1 (S1) 1.84 1.88 1.80 1.81 1.70
    Support 2 (S2) 1.76 1.84 1.75 1.69
    Support 3 (S3) 1.64 1.76 1.67
    Support 4 (S4) 1.62